
Interview with Gardiner Harris, author of The Dark Secrets of Johnson & Johnson
The book is a hard hitting expose on what went on at J&J, the pharma major, and it uncovers the secrets across the company's repertoire of drugs and products from baby powder, Tylenol, Risperdal (antipsychotic), EPO (a cancer drug), metal-on-metal hip implants, among others, all adversely impacting the health of users. Chillingly, the company continued to market them, fully cognisant of the harmful effects. In a conversation, Harris, an investigative reporter himself, describes the Herculean task he took on, and what he was up against.
In conversation with Gardiner Harris
Among all the violations that you have chronicled, what did you think was the most egregious?
J&J, early on, would find out that its product was dangerous, and would hide those dangers not only from the public, but from the FDA (Food and Drug Administration) and other regulatory agencies, knowing that it could result in a number of deaths. I estimate that at least 2 million Americans alone died from using J&J products. So it really is hard to rank order. But the worst of the worst, just in terms of sheer numbers, would probably be Risperdal. Epidemiological analysis shows that it is probably one of the most deadly drugs that has ever been sold in the U.S. It is sold to children, even though it causes boys to grow breasts and young girls to express milk. And again, the company hid those risks, lied about them in publications.
You have written about how you grew up in a J&J town. How did you move on from that to investigating the company?
I spent part of my growing up years in Princeton, New Jersey, right next to New Brunswick, where J&J is headquartered. There was a sense, growing up, that it was really a capitalistic ideal -- this was a company that both did well financially and did good in in society, and that it was seen as a sort of mom, apple pie and America all rolled into one. So when I first got the pharmaceutical beat, when I worked for The Wall Street Journal, I expected to have a wonderful time covering J&J. But my interactions with them were just the opposite and it surprised me that they were the least open with reporters, the most secretive.
When the AIDS crisis in Africa hit at the end of the 20th century and the beginning of the 21st century, the scandal around the pricing of drugs led many U.S. pharma companies to agree to allow generics companies to sell drugs in Africa. J&J was the only major manufacturer of AIDS drugs that refused to allow that. I couldn't believe it. I thought there must be some mistake, but in story after story, the image of this company ended up being entirely the opposite of what we had believed so long.
It probably hit me hardest when my own first son was born. He was born early and ended up spending days in the NICU. Soon after, I got a whole bunch of documents on J&J's heartburn drug Propulsid. Even though the company had done 20 clinical trials in children and infants, each one of which had failed to show that there was a benefit; the company nonetheless underwrote a marketing programme to sell them to infants. Not only did this drug not help these children, but it caused a QT prolongation, which is a heart arrhythmia, and for newborns, and particularly for preemies, a heart arrhythmia can be fatal.
What was J&J's response to the book?
I did cover the company for many years, I knew a lot of the executives and I certainly knew how to reach out to the company. As soon as I got the contract for this book, I told them that I'm writing this book and I would love for them to participate in it. But J&J had the same reaction it had had throughout my career -- which is to stonewall, not talk to me, not participate, and hope the story goes away.
Did you, at some time, feel a bit like Erin Brockovich?
I never looked that good; it's tough competing with Julia Roberts! But what was difficult about this process was just how dark it was, and how depressing the work often was. I spent more than five years writing this book and I go to church quite regularly. I found that I really needed that outlet throughout this process, even more than normal because I found I needed to appeal to God to help me through this, because you can lose hope. For me, it's just a very dark tale and I am thrilled, and surprised, actually, that it's gotten as many readers as it has.
Do you think that the FDA, as a regulatory agency, could have done better?
The portrait I paint of the FDA is one of real feckless disregard for protecting the public. Unfortunately, the FDA is largely funded by drug makers by what are known as user fees. The result of that is that the FDA has become captive to the very industry that it regulates. When I talk about baby powder, for instance, people had petitioned the FDA repeatedly to mandate a cancer warning on all products with talcum powder, and this would have included Johnson's baby powder. The FDA refused to answer those petitions until finally J&J lost its first baby powder case, and then suddenly, the FDA had to answer these petitions; it did so in the negative and claimed that the baby powder was fine.
In the U.S., it was the drug kingpin when it came to opioids and the FDA got a lot of criticism of its oversight of opioids. To deal with that criticism, the agency actually hired a former FDA commissioner who served on the board of directors for J&J for the previous dozen years. So, to advise the agency on how to deal with this crisis that was created by J&J, it hired a top J&J person!
How did you decide on your chosen style for the book, an engaging, but investigative journalistic piece?
I have to say, you know, as I said, the book was nearly twice as long and I ended up hiring an editor to help me not only on the decisions about which products to include in the end, but also about the style. The original version of the book had had more personal stuff and my years as a reporter covering the company. But my editors thought the reader needed a really neutral voice in telling this story. The only way that it can work is to be told in a very low-key, neutral way.
In your view, was there was a turning point when J&J could have reversed things?
I really think it was that period in the early 1980s and perhaps the late 1970s. It was Johnson's baby powder in particular, that provided the ladder down which the company itself descended into real darkness.
The Dark Secrets of Johnson & Johnson Gardiner Harris Ebury Press ₹899
ramya.kannan@thehindu.co.in
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
8 hours ago
- Hindustan Times
As cases rise, Meghalaya says it may mandate HIV/AIDS testing before marriage
SHILLONG: Meghalaya health minister Ampareen Lyngdoh on Thursday said the state could make pre-marital testing for HIV mandatory across the state as one of the steps to curb the rising incidence of HIV/AIDS. Ampareen Lyngdoh said HIV/AIDS cases in East Khasi Hills alone have doubled to 3,432, but only 1,581 patients were under treatment (X/ampareenlyngdoh) 'We are mentally prepared to take strong actions,' Lyngdoh said after a meeting chaired by deputy chief minister Prestone Tynsong and eight legislators from the East Khasi Hills to discuss the rising cases of HIV in their constituencies. 'The numbers are scary. And it's time Meghalaya takes the monster by its neck,' Lyngdoh declared. Lyngdoh said HIV/AIDS cases in East Khasi Hills alone have doubled to 3,432, but only 1,581 patients were under treatment. She added that 681 patients hadn't turned up for follow-ups, raising red flags over the state's ability to retain patients within the treatment net. 'Today, we discussed only East Khasi Hills. But the most alarming numbers are actually from West and East Jaiñtia Hills. The virus is no longer a threat—it's a full-blown crisis,' she warned. The minister said the government would refrain from disclosing location-specific data to prevent stigma but confirmed that Meghalaya's HIV/AIDS burden has reached critical levels. In this context, she said the government was seriously considering making HIV testing compulsory before marriage. 'If Goa can do it, why can't Meghalaya?' Lyngdoh asked, adding that the state may introduce laws for the community's well-being. Lyngdoh said they would now sit with legal experts and the department to see how legislation of this nature can be framed. We're no longer in denial,' the minister said. To be sure, Goa - like Maharashtra and Andhra Pradesh – has debated the idea of mandating pre-marital testing for nearly two decades but has not enacted a law. For one, it has been argued that mandating testing before marriage would have limited utility if people were having pre-marital sex. UNAIDS and WHO also strongly oppose mandatory or compulsory HIV testing and advocate for voluntary, confidential testing with informed consent. Lyngdoh said the challenge also lies in ramping up testing and ensuring access to Antiretroviral Therapy (ART). Citing government data, Lyngdoh revealed that 159 patients have died after dropping out of ART treatment, which she called an 'unacceptable' figure. 'HIV/AIDS is not a death sentence. It is manageable like cancer or TB—there's a clear treatment protocol. We just need people to come forward,' she said. However, a large number of people remain reluctant to get tested, which hinders surveillance and treatment efforts. 'There are likely many more in our communities who remain undiagnosed. That's the scariest part,' she cautioned. The minister said unlike other states, Meghalaya hadn't been able to identify the population of injecting drug users. 'That tells us our testing and tracking systems need urgent overhaul,' Lyngdoh said. The government plans to hold region-wise consultations across Garo Hills and Jaiñtia Hills, involving senior doctors and bureaucrats, before finalising a new policy. The policy blueprint, once prepared, will be brought before the cabinet.


Time of India
21 hours ago
- Time of India
Boston Scientific lifts annual profit forecast, sees smaller tariff impact
Bengaluru: Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices , and trimmed its expectation for tariff-related costs to half of the previously projected amount. Shares of the company rose 4.8% in morning trading following the results. "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100 million, down from a $200 million estimate," CFO John Monson said during a call with analysts. The company expects to offset the remaining tariff impact through strong sales performance, favorable product mix and spending control, Monson added. A rise in surgical procedures has boosted sales for medical device makers such as Boston Scientific, helping counter broader concerns about healthcare spending. Executives credited strong trial results and expanded product indications for fueling physician adoption of key cardiovascular devices such as Watchman and Farapulse, the firm's main growth drivers that saw steady quarterly demand. The company said the proposed rules by the Centers for Medicare & Medicaid Services regarding certain cardiac procedures would further benefit its technologies. Farapulse, which is approved in the U.S. for some patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the pulsed field ablation (PFA) market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. JP Morgan analyst Robbie Marcus said the profit forecast raise was larger than many had expected, especially given Boston Scientific is now moving past the initial U.S. rollout of Farapulse. "That said, the outlook still appears conservative to us," Marcus added. Boston Scientific now expects 2025 adjusted profit of $2.95 to $2.99 per share, up from its prior view of $2.87 to $2.94.


News18
a day ago
- News18
Man Finds Worm In Food Served At Rameshwaram Cafe's Bengaluru Airport Outlet
Last Updated: A passenger at Bengaluru airport found a worm in his breakfast at a Rameshwaram Cafe outlet. The staff initially tried to cover it up but later apologised to him. A passenger at the Bengaluru airport found a worm in the food served to him at the outlet of a prominent cafe, NDTV reported. The incident happened on Thursday morning, when the passenger had visited an outlet of the popular Rameshwaram Cafe at the Kempegowda International Airport in Bengaluru. According to the report, the passenger had ordered Pongal for breakfast at the airport. As he confronted the staff over the worm in his food and raised a complaint, they initially tried to cover up the incident. However, the staff members apologised to him as he began recording a video of the food served to him, the report claimed. He was later issued a full refund of Rs 300 for the item he had ordered. Bengaluru's Rameshwaram Cafe formed headlines in March last year, when an IED explosion at one of its outlets in the city injured many people. In December last year, A passenger at Jaipur International Airport found a cockroach in his bread pakora, highlighting food safety concerns. He alleged the staff were not listening to his complaints. Later, a purported video of Gaikwad allegedly slapping a canteen worker went viral on social media. In response to the complaints of the MLA, the state's Food and Drug Administration (FDA) briefly suspended the license of Ajanta Caterers, the manager of the Akashwani canteen. The FDA officials also took food samples from the Akashvani MLA canteen. Even as the controversy flared, Gaikwad refused to apologise and said that he had 'no regrets" for his actions, saying that the food in the canteen was akin to poison. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.